Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Dual GIP & GLP-1 Receptor Agonist | Once-Weekly Administration
Tirzepatide is a dual-action compound studied for its theoretical engagement of both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. Research suggests this dual-receptor activity may theoretically offer enhanced metabolic support compared to single-agonist compounds, with potential implications for weight management and glucose regulation.
Dual GIP & GLP-1 Receptor Agonist | Once-Weekly Administration
Tirzepatide is a dual-action compound studied for its theoretical engagement of both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. Research suggests this dual-receptor activity may theoretically offer enhanced metabolic support compared to single-agonist compounds, with potential implications for weight management and glucose regulation.